Roche: CINtec PLUS test supported by WHO

(CercleFinance.com) - Roche announces that the WHO has included its dual-stain cytology test (CINtec PLUS) in its guidelines on cervical cancer prevention, underlining the Swiss healthcare group's role in pioneering solutions against this disease.


It is the only US FDA-approved, CE-marked, dual-stain test that identifies human papillomavirus (HPV)-positive individuals at highest risk of developing pre-cancer and cervical cancer.

It can thus reduce the number of women undergoing unnecessary colposcopy procedures, while enabling earlier intervention for those at higher risk of developing cancer.


Copyright (c) 2024 CercleFinance.com. All rights reserved.